Article Details

Arcturus Therapeutics Advances Phase 2 Trials for Breakthrough CF and OTC Deficiency Treatments

Retrieved on: 2025-01-06 21:20:46

Tags for this article:

Click the tags to see associated articles and topics

Arcturus Therapeutics Advances Phase 2 Trials for Breakthrough CF and OTC Deficiency Treatments. View article details on hiswai:

Summary

The article focuses on Arcturus Therapeutics' Phase 2 trials for mRNA therapies targeting cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency. Tags emphasize RNA technology and focus areas. The concept of 'COVID Vaccine' is not directly mentioned but relates to Arcturus' broader mRNA platform expertise.

Article found on: www.stocktitan.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up